QNRX Stock Analysis: Buy, Sell, or Hold?
QNRX - Quoin Pharmaceuticals, Ltd. American Depositary Shares
$3.83
0.58 (17.85%)
▲
5d:
-14.13%
30d:
-19.71%
90d:
-52.12%
WAIT
LOW Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When QNRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: QNRX is down 14.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: QNRX is down 14.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: QNRX is currently trading at $3.83, which is considered oversold relative to its 30-day fair value range of $4.22 to $5.09.
Technical Outlook: Technically, QNRX is in a strong downtrend. The price is currently testing key support at $4.11. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 17.8% recently.
Market Sentiment: QNRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.40 (+458.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, QNRX is in a strong downtrend. The price is currently testing key support at $4.11. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 17.8% recently.
Market Sentiment: QNRX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.40 (+458.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.22 -
$5.09
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+17.8%)
- BULLISH: Trading 458.7% below Wall St target ($21.40)
- WARNING: Recommendation downgraded due to -14.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$4.22 -
$5.09
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.11
Resistance Level
$5.14
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.32
Wall Street Target
$21.40
(+458.7%)
Share & Embed Analysis
Last updated: June 24, 2026 5:07 PM ET
Data refreshes hourly during market hours. Next update: 6:07 PM
Data refreshes hourly during market hours. Next update: 6:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QNRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 60 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 61 BUY |
